Advaxis, Inc., a clinical-stage biotechcompany developing the next generation of immunotherapies for cancer and infectious diseases, Sunday reported conclusive 12-month overall survival and additional data from Lm-LLO-E7-15, a randomized phase 2 study evaluating the safety and efficacy of ADXS-HPV +/- cisplatin in patients with recurrent cervical cancer.

I’d like to bring your attention to what we think is a very promising publicly traded company called Target Energy Limited.

The company currently has oil well operations ongoing in the United States and is generating revenue for it’s shareholders. We’d like you to start your research immediately and put this company on your watch list. Its trading price in Australia on the ASX is $.060 and in the US on the OTCQX it’s $6.50.

It’s almost impossible to talk about the economy and living standards without eventually getting caught up in a sometimes polarizing discussion about the high cost of healthcare. Spending for healthcare, as a percentage of GDP, has grown almost everywhere in the world, including the United States. Public resentment remains understandably high in this country as the pharmaceutical industry becomes bigger and more influential, generating a sense that the largest players are starting to depend more on marketing and lobbying than on visionary research.

Target Energy Limited (TEXQY)